Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology,
Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

December 2025

Anatomic pathology selected abstracts

December 2025—Unusual morphologic patterns of breast carcinoma can raise diagnostic consideration for metastasis or special breast cancer subtypes and, thereby, impact clinical management and treatment. The authors conducted a study in which they described rare invasive breast cancers that mimic serous carcinoma of the gynecologic tract (serous-like breast carcinomas, SLBC) and characterized their clinicopathologic, immunophenotypic, and genetic features. The patients evaluated in the study were female (n = 15; median age, 49 years) and did not have a history of gynecologic malignancy. SLBC were characterized histologically by angulated, branched, sometimes anastomosing glands with micropapillary or pseudopapillary luminal projections in desmoplastic stroma. Most SLBC were triple negative (n = 10) or HER2 positive (n = 2) and grade 2 or 3, while some were estrogen receptor low positive/HER2 negative and low grade (n = 3). CK5/6 was positive irrespective of grade or receptor status (10 of 10).

Molecular pathology selected abstracts

December 2025—Two studies explore the evolution of Mycobacterium tuberculosis and the significance of GATA1 mutations in children with Down syndrome. The first study reveals diversity in virulence gene expression across Mtb clinical isolates, with variants in the regulator whiB6 linked to decreased expression of virulence factors and increased transmission of drug-resistant strains. The second study investigates the clinical significance of GATA1 mutations in neonates with Down syndrome, finding that the presence of GATA1s mutations at birth is a strong predictor of myeloid leukemia associated with Down syndrome (ML-DS).

Newsbytes

December 2025—Mayo Clinic recently introduced Mayo Clinic Platform_Insights, an offering designed to advance the adoption of artificial intelligence by giving health care organizations around the world access to Mayo Clinic’s digital expertise, data-driven insights, and clinical knowledge. “When organizations partner with us, they gain access to proven clinical and administrative solutions and the technical framework to integrate them seamlessly,” according to a press statement from Maneesh Goyal, chief operating officer for Mayo Clinic Platform, an initiative that brings together health systems, innovators, and researchers to support responsible AI development worldwide.

Q&A column

December 2025
Q. Now that the CMS allows direct observation for competency assessment to be performed virtually, does the CAP also allow it? If so, can you provide guidance? Read answer.

Q. We have implemented quality control at 10x in accordance with the Westgard rules. I use three levels of QC. If the results of two levels of QC are moving properly above and below the mean and only one level is showing a trend of a 10x rule violation, what corrective action should I take? Read answer.

Put It on the Board

December 2025—A new Clinical and Laboratory Standards Institute document on external laboratory transport is expected to be released early next year. “It’s the first comprehensive framework for evaluating external specimen transport systems,” says Joe Wiencek, PhD, D(ABCC), document development chair and medical director and associate professor of pathology, microbiology, and immunology at Vanderbilt University Medical Center.